Page last updated: 2024-09-03

way 100135 and 4-(3-3,4-p-menthadien-(1,8)-yl)olivetol

way 100135 has been researched along with 4-(3-3,4-p-menthadien-(1,8)-yl)olivetol in 1 studies

Compound Research Comparison

Studies (way 100135)	Trials (way 100135)	Recent Studies (post-2010) (way 100135)	Studies (4-(3-3,4-p-menthadien-(1,8)-yl)olivetol)	Trials (4-(3-3,4-p-menthadien-(1,8)-yl)olivetol)	Recent Studies (post-2010) (4-(3-3,4-p-menthadien-(1,8)-yl)olivetol)
143	0	34	27	0	17

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Abe, K; Egashira, N; Fujiwara, M; Hayakawa, K; Ikeda, T; Iwasaki, K; Mishima, K	1

Other Studies

1 other study(ies) available for way 100135 and 4-(3-3,4-p-menthadien-(1,8)-yl)olivetol

Article	Year
Cannabidiol prevents cerebral infarction via a serotonergic 5-hydroxytryptamine1A receptor-dependent mechanism. Stroke, 2005, Volume: 36, Issue:5 Topics: Animals; Arachidonic Acids; Cannabidiol; Cerebral Infarction; Cerebrovascular Circulation; Endocannabinoids; Infarction, Middle Cerebral Artery; Male; Mice; Neuroprotective Agents; Piperazines; Polyunsaturated Alkamides; Receptor, Serotonin, 5-HT1A; Resorcinols; Serotonin 5-HT1 Receptor Antagonists; Serotonin Antagonists	2005

Article

Year

Cannabidiol prevents cerebral infarction via a serotonergic 5-hydroxytryptamine1A receptor-dependent mechanism.

Stroke, 2005, Volume: 36, Issue:5

Topics: Animals; Arachidonic Acids; Cannabidiol; Cerebral Infarction; Cerebrovascular Circulation; Endocannabinoids; Infarction, Middle Cerebral Artery; Male; Mice; Neuroprotective Agents; Piperazines; Polyunsaturated Alkamides; Receptor, Serotonin, 5-HT1A; Resorcinols; Serotonin 5-HT1 Receptor Antagonists; Serotonin Antagonists

2005